COLL
NASDAQ · Pharmaceuticals
Collegium Pharmaceutical Inc
$29.47
+0.36 (+1.24%)
Financial Highlights (FY 2026)
Revenue
638.12M
Net Income
51.40M
Gross Margin
59.3%
Profit Margin
8.1%
Rev Growth
+18.9%
D/E Ratio
3.09
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 59.3% | 59.3% | 35.1% | 35.1% |
| Operating Margin | 21.0% | 18.9% | 21.2% | 20.6% |
| Profit Margin | 8.1% | 7.7% | 14.1% | 14.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 638.12M | 536.50M | 486.77M | 543.10M |
| Gross Profit | 378.72M | 318.41M | 171.09M | 190.89M |
| Operating Income | 133.75M | 101.21M | 103.40M | 112.13M |
| Net Income | 51.40M | 38.89M | 68.71M | 79.42M |
| Gross Margin | 59.3% | 59.3% | 35.1% | 35.1% |
| Operating Margin | 21.0% | 18.9% | 21.2% | 20.6% |
| Profit Margin | 8.1% | 7.7% | 14.1% | 14.6% |
| Rev Growth | +18.9% | +18.9% | +18.7% | -0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 353.84M | 353.84M | 505.83M | 501.20M |
| Total Equity | 114.67M | 114.67M | 1.10B | 1.07B |
| D/E Ratio | 3.09 | 3.09 | 0.46 | 0.47 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 137.20M | 109.58M | 134.63M | 134.48M |
| Free Cash Flow | — | — | 97.48M | 99.20M |